Mission Bio delivers targeted single-cell genomics solutions for high-impact applications with Tapestri, the Precision Genomics Platform. Tapestri is the industry’s first targeted single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate seamlessly with existing NGS workflows. With Tapestri, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

Raising a Series A is a huge accomplishment and closing it might feel like you’ve crossed the finish line but the pressure only goes up from here.

Mighty Capital is hiring an exceptional individual to join us as an AssociatePrincipal and have a direct impact our organization. They will be responsible for managing the deal flow, performing analysis, coordinating partner and volunteer activities, and taking on other ad-hoc tasks. Strong interpersonal skills, strategic thinking with exceptional analytical and presentation skills, high energy and a service mindset approach are a must. To apply: email you cover letter and resume to sc@mighty.capital with the title “Candidate for the Associate/Principal position: <your name>”

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced a first-of-its-kind study demonstrating its ability to perform single-cell DNA analysis at speed and scale orders of magnitude higher than prior methods. The study, published in Genome Research and co-authored by researchers at Mission Bio and MD Anderson Cancer Center, illustrates its Tapestri platform’s ability to identify the evolution of cellular mutations in Acute Myeloid Leukemia (AML) tumors. This study provides unprecedented insight into the cells that drive complex diseases like cancer and opens the door to the routine sequencing of tumors.

In this article commissioned by Business Insider, Melia Robinson examines how venture capital firms are specializing in order to compete for hot investment deals. This article includes Mighty Capital as an example of this trend and also re-shares quotes from Managing Partner, SC Moatti’s previous interview and 7/17/2018 Business Insider article also written by Melia Robinson.

Today, we’ll explore three strategies that lead to healthcare sales “wins” and point out how we can tell if the teams we meet in our screenings have what it takes to deploy them. Those 3 business behaviors are: Arbitrage, Stories and Leverage

In this article commissioned by Business Insider, Mighty Capital Managing Partner SC Moatti discusses social influence and what makes the venture firm stand out from the pack from other startups.

In this article commissioned by Fortune, Mighty Capital Managing Partner SC Moatti answers 5 questions on being a dealmaker:

1. TERM SHEET: Why did you launch a $13 million fund at a time when we’re seeing more and more firms raise mega-funds?
2. You say that a lot of Silicon Valley firms create “artificial differentiation.” What do you mean by that?
3. What do you think about the effect mega-funds, such as SoftBank’s $100 billion Vision Fund, are having on the ecosystem?
4. What are product managers talking about right now?
5. You don’t like talking about diversity at your firm. Why?

The venture capital industry is male dominated and some of its unfair practices have been brought to light with the rise of the #metoo movement in 2017. This got us to wonder: How do businesses approach diversity and inclusion? What does that mean for Mighty Capital? What does that mean for our portfolio? We have been committed to diversity and inclusion from day 1 and it’s an essential part of our culture that we summarize with Mark Twain’s famous quote: “Actions Speak Louder Than Words.”